The probability of chronic hepatitis B is relatively low, and the cure rate varies with different treatment regimens. Chronic hepatitis B is a common infectious liver disease that can cause continuous liver damage and may even lead to some end - stage liver diseases. Therefore, sufficient attention and regular treatment should be given to chronic hepatitis B. The treatment of chronic hepatitis B remains a challenge in current clinical practice. There is no mature plan to completely eradicate hepatitis B in a short period. Most patients need long - term antiviral treatment, which results in a very low cure rate of hepatitis B. However, with the current attempts at some potent antiviral drugs and some good antiviral treatment regimens, the cure rate of chronic hepatitis B has been improved to a certain extent. For example, for a part of the advantaged population, mainly patients with relatively low viral loads or low surface antigen levels, using pegylated interferon in combination with oral nucleoside drugs for antiviral treatment can achieve a hepatitis B cure rate of about 30%. That is, the seroconversion rate of surface antigen has been significantly improved, achieving the effect of clinical cure of hepatitis B.